Oncotelic Therapeutics, Inc. (OTCQB: OTLC), in collaboration with Sapu Nano, announced that the first patient has been dosed in the Phase 1b clinical trial of Sapu003, an investigational intravenous Deciparticle formulation of everolimus. The open-label, dose-escalation study is designed to assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced mTOR-sensitive solid tumors. The trial includes cohorts for HR-positive/HER2-negative breast cancer and multiple additional tumor types.
Sapu003 is a weekly IV formulation intended to address limitations associated with oral everolimus delivery, such as variable absorption and dose-limiting toxicity. This approach could potentially improve the therapeutic index of everolimus, a drug commonly used in oncology but often hindered by oral administration challenges. The Phase 1b study marks a critical step in evaluating whether this new formulation can offer better patient outcomes.
The importance of this trial lies in its potential to expand treatment options for patients with mTOR-sensitive cancers. Everolimus is known to inhibit the mTOR pathway, which is frequently dysregulated in various cancers. By developing an IV formulation, Oncotelic aims to achieve more consistent drug exposure and possibly reduce side effects, which could enhance patient compliance and quality of life.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. The company targets high-unmet-need cancers and rare pediatric indications with late-stage therapeutic candidates. Beyond its internal pipeline, Oncotelic benefits from a robust portfolio of inventions from its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes.
Additionally, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. It currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that strengthens its position in oncology and rare disease therapeutics.
The trial's progression could have significant implications for the treatment landscape of mTOR-sensitive tumors. If successful, Sapu003 may provide a more reliable and tolerable treatment option, potentially benefiting a wide range of patients. The use of Deciparticle technology could also set a precedent for reformulating other oral oncology drugs to improve their pharmacokinetic profiles.
For more information, the full press release is available at https://ibn.fm/JuGIs. Updates on Oncotelic can be found in their newsroom at https://ibn.fm/OTLC.
